ABSTRACT
The synthesis of TBA-DASA-POM-DASA, the first photoactive covalent hybrid polyoxometalate (POM) incorporating a donor-acceptor Stenhouse adduct (DASA) reverse photochrome, is presented. It has been evidenced that in solution the equilibrium between the colorless cyclopentenone and the highly colored triene conformers is strongly dependent not only on the nature of the solvent but also the countercations, allowing to tune its optical properties. This complex has been further associated to photochromic spironaphtoxazine cations, resulting in a material which can be activated by two distinct optical stimuli. Moreover, when combined with N-methyldiethanolamine, TBA-DASA-POM-DASA constitutes a performing photoinitiating system for polyethylene glycol diacrylate polymerization and under visible light irradiation, a promising result in a domain scarcely developed in POM chemistry.
ABSTRACT
A unique polyoxometalate complex made up of a tetradecanuclear nickel bisphosphonate cluster capping a {SiW9} unit has been characterized. This stable compound exhibits a high hydrogen evolution reaction photocatalytic activity under visible light irradiation via a reductive quenching mechanism.
ABSTRACT
Three polyoxometalates (POMs) functionalized by tetrathiafulvalene (TTF) molecules have been synthesized by a coupling reaction between the Anderson-type POMs [MnMo6O18{(OCH2)3CNH2}2]3- or [AlMo6O18(OH)3{(OCH2)3CNH2}]3- and the TTF carboxylic acid derivative (MeS)3TTF(S-CH2-CO2H). The monofunctionalized TTF-AlMo6 POM contains one TTF group covalently grafted on an Al Anderson platform. The symmetrical TTF-MnMo6-TTF POM possesses two TTF groups grafted on each side of a Mn Anderson derivative while the asymmetrical TTF-MnMo6-SP POM contains a TTF and a spiropyran groups. These three trianionic species have been characterized by elemental analysis, 1H and 13C NMR, FT-IR spectroscopy, ESI-MS spectrometry, and single-crystal X-ray diffraction (for TTF-MnMo6-TTF). In the solid state, the grafted TTF molecules of TTF-MnMo6-TTF POMs interact via S···S and π···π interactions and form chains. The electrochemical properties of the complexes reflect the contributions of both the inorganic POM and the TTF moieties. Despite adsorption of the oxidized hybrid species on the Pt grid working electrode, UV-vis-NIR spectroelectrochemical investigations evidence peaks characteristic of the oxidation of the TTF units. Finally, hyper-Rayleigh scattering (HRS) measurements show that the three novel TTF derivatives exhibit ß values between 20 and 37 × 10-30 esu. Moreover it is observed that the oxidation of the TTF moieties by Fe3+ ions increases the NLO response. These values are in the order of magnitude of that found for the well-known 4-dimethylamino- N-methyl-4-stilbazolium (DAS+) cation (ß = 60 × 10-30 esu).
ABSTRACT
We synthesized a series of polyoxometalate-bisphosphonate complexes containing MoVIO6 octahedra, zoledronate, or an N-alkyl (n-C6 or n-C8) zoledronate analogue, and in two cases, Mn as a heterometal. Mo6L2 (L = Zol, ZolC6, ZolC8) and Mo4L2Mn (L = Zol, ZolC8) were characterized by using single-crystal X-ray crystallography and/or IR spectroscopy, elemental and energy dispersive X-ray analysis and 31P NMR. We found promising activity against human nonsmall cell lung cancer (NCI-H460) cells with IC50 values for growth inhibition of â¼5 µM per bisphosphonate ligand. The effects of bisphosphonate complexation on IC50 decreased with increasing bisphosphonate chain length: C0 ≈ 6.1×, C6 ≈ 3.4×, and C8 ≈ 1.1×. We then determined the activity of one of the most potent compounds in the series, Mo4Zol2Mn(III), against SK-ES-1 sarcoma cells in a mouse xenograft system finding a â¼5× decrease in tumor volume than found with the parent compound zoledronate at the same compound dosing (5 µg/mouse). Overall, the results are of interest since we show for the first time that heteropolyoxomolybdate-bisphosphonate hybrids kill tumor cells in vitro and significantly decrease tumor growth, in vivo, opening up new possibilities for targeting both Ras as well as epidermal growth factor receptor driven cancers.
